The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Oncology, Cancer and Surgery. His Prostate cancer research focuses on Prostate-specific antigen in particular. His study connects Placebo and Internal medicine.
His Oncology research includes themes of Cabazitaxel, Circulating tumor cell, Immunology, Sipuleucel-T and Disease. His studies deal with areas such as Genome-wide association study and Single-nucleotide polymorphism as well as Cancer. His Surgery study integrates concerns from other disciplines, such as Watchful waiting, Rectal examination and Urology.
Chris Parker focuses on Prostate cancer, Internal medicine, Oncology, Surgery and Radiation therapy. Prostate cancer is the subject of his research, which falls under Cancer. His Prostate-specific antigen, Randomized controlled trial, Chemotherapy and Hazard ratio study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.
His research in Oncology intersects with topics in Clinical trial, Radium-223, Androgen deprivation therapy, Gynecology and Disease. His Surgery research incorporates elements of Placebo and Watchful waiting. Chris Parker interconnects Prostatectomy and Hormone therapy in the investigation of issues within Radiation therapy.
His primary scientific interests are in Prostate cancer, Internal medicine, Oncology, Radiation therapy and Prostate. Prostate cancer is a subfield of Cancer that he explores. His Cancer study incorporates themes from Biopsy and Magnetic resonance imaging.
As part of his studies on Internal medicine, Chris Parker frequently links adjacent subjects like Life expectancy. His biological study spans a wide range of topics, including Chemotherapy, Docetaxel, Androgen deprivation therapy, Hazard ratio and Prostate radiotherapy. His study looks at the relationship between Radiation therapy and topics such as Prostatectomy, which overlap with Urology.
His main research concerns Prostate cancer, Internal medicine, Oncology, Hazard ratio and Androgen deprivation therapy. His Prostate cancer study deals with the bigger picture of Cancer. Chris Parker has researched Cancer in several fields, including Biopsy and Radiology.
His study explores the link between Internal medicine and topics such as Placebo that cross with problems in Asymptomatic, Survival rate, Prostvac and Phases of clinical research. Overall survival, Consensus conference, Abiraterone and Hormone is closely connected to Hormone sensitive prostate cancer in his research, which is encompassed under the umbrella topic of Oncology. Chris Parker focuses mostly in the field of Hazard ratio, narrowing it down to matters related to Proportional hazards model and, in some cases, Apalutamide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle.
The New England Journal of Medicine (2013)
Abiraterone and increased survival in metastatic prostate cancer.
Chris Parker;Oliver Sartor.
The New England Journal of Medicine (2011)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono;Howard I. Scher;R. Bruce Montgomery;Christopher Parker.
Clinical Cancer Research (2008)
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
Hashim U Ahmed;Hashim U Ahmed;Ahmed El-Shater Bosaily;Ahmed El-Shater Bosaily;Louise C. Brown;Rhian Gabe.
The Lancet (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke.
The New England Journal of Medicine (2017)
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud.
Journal of Clinical Oncology (2008)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason.
The Lancet (2016)
Multiple newly identified loci associated with prostate cancer susceptibility.
Rosalind A Eeles;Rosalind A Eeles;Zsofia Kote-Jarai;Graham G Giles;Graham G Giles;Ali Amin Al Olama.
Nature Genetics (2008)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley;Isabel Syndikus;Helen Mossop;Vincent Khoo.
Lancet Oncology (2016)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker.
Journal of Clinical Oncology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: